Wockhardt Limited (WOCKPHARMA.BO)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Habil Fakhruddin Khorakiwala | Founder & Executive Chairman | 36.5M | -- | 1941 |
| Dr. Murtaza Habil Khorakiwala | MD & Executive Director | 21.2M | -- | 1973 |
| Dr. Huzaifa Habil Khorakiwala | Executive Director | 21.2M | -- | 1971 |
| Mr. Deepak R. Madnani | Chief Financial Officer | -- | -- | -- |
| Dr. Mahesh Vithalbhai Patel | Chief Scientific Officer of New Drug Discovery | -- | -- | -- |
| Ms. Debolina Partap | Senior Vice President of Legal | -- | -- | -- |
| Mr. Neeraj Agarwal | Chief Human Resource Officer | -- | -- | -- |
| Mr. Anil V. Kamath AMRSH (Lon.), BCom (Hons), MBIM (Lon.), MIMA | Senior Vice President of Business Development | -- | -- | 1951 |
| Mr. Zoher T. Sihorwala | Head of Global Regulatory Affairs | -- | -- | 1970 |
| Mr. Prakash Gupta | President of Supply Chain | -- | -- | -- |
Wockhardt Limited
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 2,386
Description
Wockhardt Limited, a pharmaceutical and biotech company, manufactures and trades pharmaceuticals, medicinal, botanical, and chemical products in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. The company develops qualified infectious diseases products comprising WCK5222, which is in phase 3 clinical trial for the treatment of sepsis and hospital/ventilator associated pneumonia; WCK 4282, which is in phase 3 clinical trial for ESBL infections; WCK 6777, which is phase 1 to treat gram negative infections; and WCK 4873, which is phase 3 clinical trial for community-acquired bacterial pneumonia. It also offers rapid and long-acting insulin analogues, concentrated insulins, GLP1 analogues, haemopoietins, biobetters and novel products, and delivery devices. In addition, the company develops and commercializes Biovac-B, a hepatitis B vaccine; WEPOX, a recombinant human erythropoietin; WOSULIN, a recombinant human insulin; and GLARITUS, a recombinant insulin glargine. Further, it provides contract manufacturing services; offers and active pharmaceutical ingredients. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
Corporate Governance
Upcoming Events
May 26, 2025 at 10:59 AM UTC - May 30, 2025 at 12:00 PM UTC
Wockhardt Limited Earnings Date
Recent Events
November 17, 2016 at 12:00 AM UTC
Ex-Dividend Date